Hologic, Inc. (HOLX) GYN Surgical is expected to have registered vital contributions from MyoSure and the Related fluid system, with an increasing contribution from its laparoscopic portfolio.Moreover, Hologic’s Molecular Diagnostics business is likely to register strong growth driven by a combination of newer assays like BV and CV/TV.We anticipate HOLX’s second-quarter fiscal 2024 performance, scheduled for release on May 2 after the closing bell, to reflect these aspects.Click here to know how the company ...